Patents Assigned to REGENERON PHARMACEUTIALS, INC.
  • iRNA Compositions and Methods for Targeting ANGPTL7
    Publication number: 20240409943
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting ANGPTL7. The invention also relates to methods of using such dsRNA compositions to inhibit expression of ANGPTL7 and to methods of treating ANGPTL7-associated disorders, e.g., glaucoma, using such dsRNA compositions.
    Type: Application
    Filed: October 1, 2022
    Publication date: December 12, 2024
    Applicants: ALNYLAM PHARMACEUTICALS, INC., REGENERON PHARMACEUTIALS, INC.
    Inventors: JAMES D. MCININCH, VASANT R. JADHAV, BHAUMIK A. PANDYA, ELENA CASTELLANOS-RIZALDOS, ADAM CASTORENO, CARMELO ROMANO, GAURANG PATEL, YING HU